http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PH-12020500417-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcce39a20bef16c3f04497659caba40f
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6849
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6803
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2863
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40
filingDate 2020-03-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f75c0800b8975f37c915736e35c53c95
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_57937a7dfc9334967c93474d21f85e0a
publicationDate 2021-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber PH-12020500417-A1
titleOfInvention Anti-efgr antibody drug conjugates (adc) and uses thereof
abstract The present disclosure provides antibody-drug conjugates (ADCs) comprising a cytotoxic or cytostatic agent linked to an anti-EGFR antibody by way of a linker, compositions comprising the ADCs, methods of making the ADCs, and methods of treating a cancer comprising administering the ADCs to a subject having cancer. The present disclosure provides ADCs that specifically bind EGFR, and in particular human EGFR (hEGFR). The anti-EGFR Ab described herein comprises a S239C mutation in a heavy chain constant region, wherein the numbering is in accordance with Kabat. In certain embodiments, the heavy chain constant region of the anti-EGFR antibody either lacks a C-terminal lysine or comprises an amino acid other than lysine at a C-terminus of the heavy chain constant region.
priorityDate 2017-09-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID38532
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID458396425
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419554042

Total number of triples: 25.